ExpressCT value Leverage GenomicsNext’s ctDNA based gene expression inference to offer dynamic tumor profiling as a companion diagnostic tool for antibody-drug conjugates and emerging therapies, highlighting faster, liquid-biopsy based decision support.

Strategic partnerships Target collaborations with biopharma, diagnostic developers, and researchers seeking expression-driven biomarkers to enrich clinical trials and expand access to RNA-based diagnostics, leveraging Tempus collaborations for PurIST integration.

Expansion opportunities Position ExpressCT Rewind as a capability to monetize existing liquid biopsy DNA sequencing data, enabling retroactive insights for customers with prior tests and expanding service scope without new sample collection.

Financial momentum capitalize on a recent Series C financing and multi-year growth trajectory to fund commercialization, scale the GenomicsNext platform, and accelerate market entry with validated biomarker discovery capabilities.

Technical fit Promote the tech stack and cloud-based infrastructure as a selling point for scalable deployments across biopharma and diagnostics partners, emphasizing secure data handling, rapid analytics, and integration with existing data ecosystems.